
After having recently published promising data for its ABNCoV2 vaccine against Covid-19, Bavarian Nordic now begins a phase II trial for its candidate, Bavarian informs in a press release Monday morning.
"We are pleased to continue development of our Covid-19 vaccine candidate by starting this phase II trial, which we expect will confirm the high levels of neutralizing antibodies already shown by ABNCoV2 in pre-clinical studies as well as a phase I clinical trial," writes Bavarian Nordic Chief Executive Paul Chaplin in the statement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app